<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intensive chemotherapy produces a lower complete remission (CR) rate in the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) than in de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), possibly due in part to a higher incidence of P <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> (PGP) expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> blast cells </plain></SENT>
<SENT sid="1" pm="."><plain>We designed a randomized trial of intensive chemotherapy with or without <z:chebi fb="56" ids="15854">quinine</z:chebi>, an agent capable of reverting the multidrug resistance (mdr) phenotype, in patients aged &lt; or = 65 years with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were randomized to receive <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi> 12 mg/m2/d days 2-5 + AraC 1 g/m2/12 h days 1-5, with (Q+) or without (Q-) <z:chebi fb="56" ids="15854">quinine</z:chebi> (30 mg/kg/d) </plain></SENT>
<SENT sid="3" pm="."><plain>131 patients were included </plain></SENT>
<SENT sid="4" pm="."><plain>PGP expression analysis was successful in 91 patients </plain></SENT>
<SENT sid="5" pm="."><plain>In the 42 PGP-positive cases, 13/25 (52%) patients in the Q+ group achieved CR, compared to 3/17 (18%) patients in the Q- group (P = 0.02) and median Kaplan-Meier survival was 13 months in the Q+ group, and 8 months in the Q- group (P = 0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>No life-threatening toxicity was observed with <z:chebi fb="56" ids="15854">quinine</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, the results of this randomized study show that <z:chebi fb="56" ids="15854">quinine</z:chebi> increases the CR rate and survival in PGP-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases treated with intensive chemotherapy </plain></SENT>
</text></document>